The Prognostic Role of Late Gadolinium Enhancement Magnetic Resonance Imaging in Patients With Cardiomyopathy

Canadian Journal of Cardiology

Volumn 29, Issue 3, 2013, Pages 329-336

  Stirrat, John ^a   White, James A ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; DISEASE MARKER; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; LATE GADOLINIUM ENHANCEMENT; NONISCHEMIC CARDIOMYOPATHY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH;

CARDIOMYOPATHIES; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84874337459     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.11.033     Document Type: Review

References (64)

1. White J.A., Patel M.R. The role of cardiovascular MRI in heart failure and the cardiomyopathies. Cardiol Clin 2007, 25:71-95. vi.
2. Han W., Kim W.R., White J.A., Kim R.J. Magnetic resonance imaging of the heart. Hurst's The Heart 2008, McGraw Hill, New York, NY. 12th ed. V. Fuster, R.A. Walsh, R.A. Harrington, P. Poole-Wilson (Eds.).
3. Flett A.S., Hasleton J., Cook C., et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011, 4:150-156.
4. Harrigan C.J., Peters D.C., Gibson C.M., et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 2011, 258:128-133.
5. Harada T., Tomita Y., Nakagawa T., et al. Pace-mapping conduction delay at reentry circuit sites of ventricular tachycardia after myocardial infarction. Heart Vessels 1997, (suppl 12):232-234.
6. Hsia H.H., Marchlinski F.E. Characterization of the electroanatomic substrate for monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy. Pacing Clin Electrophysiol 2002, 25:1114-1127.
7. Roes S.D., Borleffs C.J., van der Geest R.J., et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging 2009, 2:183-190.
8. Schmidt A., Azevedo C.F., Cheng A., et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 2007, 115:2006-2014.
9. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006, 114:32-39.
10. Wu K.C., Gerstenblith G., Guallar E., et al. Combined cardiac magnetic resonance imaging and c-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging 2012, 5:178-186.
11. Ellims A.H., Iles L.M., Ling L.H., Hare J.L., Kaye D.M., Taylor A.J. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson 2012, 14:76.
12. Kellman P., Wilson J.R., Xue H., et al. Extracellular volume fraction mapping in the myocardium, part 2: Initial clinical experience. J Cardiovasc Magn Reson 2012, 14:64.
13. Sibley C.T., Noureldin R.A., Gai N., et al. T1 mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology 2012, 265:724-732.
14. Larose E., Rodes-Cabau J., Pibarot P., et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol 2010, 55:2459-2469.
15. Baks T., van Geuns R.J., Biagini E., et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006, 47:40-44.
16. Bello D., Fieno D.S., Kim R.J., et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005, 45:1104-1108.
17. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343:1445-1453.
18. Schvartzman P.R., Srichai M.B., Grimm R.A., et al. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. Am Heart J 2003, 146:535-541.
19. Cheong B.Y., Muthupillai R., Wilson J.M., et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation 2009, 120:2069-2076.
20. Gao P., Yee R., Gula L., et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 2012, 5:448-456.
21. Klem I., Weinsaft J.W., Bahnson T.D., et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol 2012, 60:408-420.
22. Kwon D.H., Halley C.M., Carrigan T.P., et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging 2009, 2:34-44.
23. Scott P.A., Morgan J.M., Carroll N., et al. The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2011, 4:324-330.
24. Wu K.C., Weiss R.G., Thiemann D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51:2414-2421.
25. Yokota H., Heidary S., Katikireddy C.K., et al. Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy. J Cardiovasc Magn Reson 2008, 10:17.
26. Heidary S., Patel H., Chung J., et al. Quantitative tissue characterization of infarct core and border zone in patients with ischemic cardiomyopathy by magnetic resonance is associated with future cardiovascular events. J Am Coll Cardiol 2010, 55:2762-2768.
27. Kwong R.Y., Sattar H., Wu H., et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008, 118:1011-1020.
28. Kim H.W., Klem I., Shah D.J., et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med 2009, 6:e1000057.
29. Barbier C.E., Nylander R., Themudo R., et al. Prevalence of unrecognized myocardial infarction detected with magnetic resonance imaging and its relationship to cerebral ischemic lesions in both sexes. J Am Coll Cardiol 2011, 58:1372-1377.
30. Schelbert E.B., Cao J.J., Sigurdsson S., et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 2012, 308:890-896.
31. Rouleau J.L. New and emerging drugs and device therapies for chronic heart failure in patients with systolic ventricular dysfunction. Can J Cardiol 2011, 27:296-301.
32. Bleeker G.B., Kaandorp T.A., Lamb H.J., et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 2006, 113:969-976.
33. White J.A., Yee R., Yuan X., et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2006, 48:1953-1960.
34. Ypenburg C., Schalij M.J., Bleeker G.B., et al. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. J Nucl Med 2006, 47:1565-1570.
35. Ypenburg C., Schalij M.J., Bleeker G.B., et al. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur Heart J 2007, 28:33-41.
36. Chalil S., Foley P.W., Muyhaldeen S.A., et al. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace 2007, 9:1031-1037.
37. Petryka J., Misko J., Przybylski A., et al. Magnetic resonance imaging assessment of intraventricular dyssynchrony and delayed enhancement as predictors of response to cardiac resynchronization therapy in patients with heart failure of ischaemic and non-ischaemic etiologies. Eur J Radiol 2012, 81:2639-2647.
38. Duckett S.G., Ginks M., Shetty A., et al. Adverse response to cardiac resynchronisation therapy in patients with septal scar on cardiac MRI preventing a septal right ventricular lead position. J Interv Card Electrophysiol 2012, 33:151-160.
39. Khan F.Z., Virdee M.S., Palmer C.R., et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012, 59:1509-1518.
40. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
41. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350:2151-2158.
42. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003, 108:54-59.
43. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-1985.
44. Lehrke S., Lossnitzer D., Schob M., et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 2011, 97:727-732.
45. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381:242-255.
46. Moon J.C.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
47. Quarta G., Grasso A., Pasquale F., et al. Evolution and clinical importance of fibrosis in HCM. JACC Cardiovasc Imaging 2011, 4:1221-1223.
48. Khan R., Massel D., Stirrat J., et al. Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study. Int J Cardiovasc Imaging 2013, 29:395-404.
49. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
50. Rubinshtein R., Glockner J.F., Ommen S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 3:51-58.
51. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
52. Adabag A.S., Maron B.J., Appelbaum E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
53. Kwon D.H., Smedira N.G., Rodriguez E.R., et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009, 54:242-249.
54. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC. Cardiovascular imaging 2012, 5:370-377.
55. Prinz C., Schwarz M., Ilic I., et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol 2013, 29:358-363.
56. Chan R.H., Maron B., Olivotto I., et al. Prognostic utility of contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: an international multicenter study. J Am Coll Cardiol 2012, 59(suppl 1):E1570.
57. Silverman K.J., Hutchins G.M., Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978, 58:1204-1211.
58. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005, 45:1683-1690.
59. Patel M.R., Cawley P.J., Heitner J.F., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009, 120:1969-1977.
60. Patel A.R., Klein M.R., Chandra S., et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail 2011, 13:1231-1237.
61. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 2005, 112:2047-2060.
62. Maceira A.M., Prasad S.K., Hawkins P.N., Roughton M., Pennell D.J. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008, 10:54.
63. Ruberg F.L., Appelbaum E., Davidoff R., et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009, 103:544-549.
64. Austin B.A., Tang W.H., Rodriguez E.R., et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009, 2:1369-1377.